[
    {"question": "How many infections and deaths were attributed to antibiotic-resistant bacteria in Europe in 2015?", "answer": "According to the European Center of Disease and Control (ECDC), antibiotic-resistant bacteria caused 600,000 infections and 27,000 attributable deaths in 2015 in Europe."},
    {"question": "What is the challenge faced by clinicians worldwide in prescribing antibiotics for MDR-GNB infections?", "answer": "Clinicians worldwide are faced with the challenge of prescribing antibiotics for MDR-GNB infections, being stretched between the limitations of old drugs, the fear of promoting resistance by using new antibiotics, the lack of data on the effects of newly developed antibiotics against MDR-GNB, and the high costs of new antibiotics."},
    {"question": "What is the definition of sepsis according to the sepsis-3 definition?", "answer": "Sepsis is defined as a severe presentation of infection with life-threatening organ dysfunction caused by a dysregulated host response to infection."},
    {"question": "What is the definition of septic shock according to the sepsis-3 definitions?", "answer": "Septic shock is defined as a condition where the underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality."},
    {"question": "What are considered severe infections?", "answer": "Severe infections are considered to be sepsis or septic shock."},
    {"question": "How are low and high-risk infections defined based on the INCREMENT score?", "answer": "Infections originating from a urinary tract source or biliary infections after source control are considered low-risk infections, while all other infections are considered high-risk infections."},
    {"question": "What is defined as an uncomplicated UTI?", "answer": "An uncomplicated UTI is an infection causing local bladder signs and symptoms, without fever, other signs of systemic infection, or findings suggestive of kidney involvement."},
    {"question": "What is defined as difficult-to-treat resistance (DTR)?", "answer": "Difficult-to-treat resistance (DTR) is defined as resistance to all b-lactams, including carbapenems, b-lactamase inhibitor combinations, and fluoroquinolones."},
    {"question": "What is the recommended targeted therapy for patients with BSI and severe infection due to 3GCephRE?", "answer": "For patients with BSI and severe infection due to 3GCephRE, a carbapenem (imipenem or meropenem) is recommended as targeted therapy (strong recommendation for use, moderate certainty of evidence)."},
    {"question": "What is the most commonly reported resistance mechanism in 3GCephRE studies?", "answer": "The most commonly reported resistance mechanism in 3GCephRE studies is extended-spectrum b-lactamase (ESBL) production, mostly without specifying the type of b-lactamases conferring the ESBL phenotype."},
    {"question": "What is the main comparison discussed in the context of 3GCephRE treatment?", "answer": "The main comparison is between the older BLBLI (amoxicillin-clavulanate and piperacillin-tazobactam) and carbapenems, as discussed in the MERINO RCT."},
    {"question": "What clinical syndromes are considered for the treatment of infections caused by 3GCephRE?","answer": "The clinical syndromes considered for the treatment of infections caused by 3GCephRE are BSI, UTI, pneumonia, and intraabdominal infection (IAI)."},
    {"question": "What was the comparison made in the MERINO trial among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae?","answer": "The MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae."},
    {"question": "How many observational studies compared carbapenem therapy with old BLBLI for the therapy of 3GCephRE BSI?","answer": "Twenty observational studies compared carbapenem therapy with old BLBLI for the therapy of 3GCephRE BSI."},
    {"question": "How many retrospective observational studies compared carbapenems with any other non-carbapenem antibiotic (carbapenem-sparing regimen)?","answer": "Nine retrospective observational studies compared carbapenems with any other non-carbapenem antibiotic (carbapenem-sparing regimen)."},
    {"question": "How many studies compared old BLBLI with a comparator regimen?","answer": "Three studies compared old BLBLI with a comparator regimen."},
    {"question": "How many observational studies and RCTs compared ertapenem with imipenem/meropenem?","answer": "Four observational studies and one small RCT compared ertapenem with imipenem/meropenem."},
    {"question": "How many retrospective observational cohort studies evaluated cefmetazole or flomoxef versus carbapenems for 3GCephRE BSI?","answer": "Five retrospective observational cohort studies evaluated cefmetazole or flomoxef versus carbapenems for 3GCephRE BSI."},
    {"question": "How many retrospective observational cohort studies evaluated cefepime versus carbapenems or a non-cefepime regimen?","answer": "Seven retrospective observational cohort studies evaluated cefepime versus carbapenems or a non-cefepime regimen."},
    {"question": "How were quinolones examined in the context of other antibiotics?", "answer": "Quinolones were examined individually."},
    {"question": "How many studies examined aminoglycosides?", "answer": "Aminoglycosides were examined specifically in a single study."},
    {"question": "What antibiotic was intravenous fosfomycin compared with in the ZEUS study?", "answer": "Piperacillin-tazobactam"},
    {"question": "What was the outcome of the subgroup analysis of an RCT comparing plazomicin with meropenem in terms of microbiological cure for cUTI caused by 3GCephRE Enterobacterales?", "answer": "Plazomicin was not significantly different from meropenem, with a risk difference of 7.4 (95% CI -9.6 to 23.1) and a low risk of bias."},
    {"question": "How many RCTs evaluated carbapenems versus beta-lactam/beta-lactamase inhibitor (BLBLI) combinations?", "answer": "One RCT evaluated carbapenems versus BLBLI combinations."},
    {"question": "What was the outcome of the comparison between cephamycins and cefepime versus carbapenems in retrospective cohort studies for the treatment of pyelonephritis caused by 3GCephRE?", "answer": "None of the studies found statistically significant differences between groups, but the evidence was of low certainty due to high risk of bias and small sample sizes (10-23 patients)." },
    {"question": "What type of study compared temocillin with carbapenems in terms of effective antibiotic therapy duration?", "answer": "A matched case-control study with 144 patients compared temocillin with carbapenems."},
    {"question": "What was the outcome of the comparison between carbapenems and non-carbapenem antibiotics in terms of clinical cure and microbiological outcomes in two retrospective studies?", "answer": "The studies did not reveal significant differences in clinical cure and microbiological outcomes, but had a high risk of bias."},
    {"question": "What was the outcome of the comparison between ceftazidime-avibactam and carbapenems or best available therapy in terms of clinical failure and microbiological cure in RCTs for 3GCephRE UTI?", "answer": "There were no significant differences between groups in clinical failure, but ceftazidime-avibactam showed an advantage in microbiological cure in one trial, with high certainty of evidence."},
    {"question": "What was the focus of the subgroup analyses in several RCTs that included patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP)?", "answer": "The subgroup analyses focused on patients with pneumonia caused by 3GCephRE, comparing imipenem and tigecycline, and included a total of 41 patients."},
    {"question": "What was the comparison made in the subgroup of patients with intra-abdominal infections caused by 3GCephRE in some syndrome-directed IAI antibiotic-approval RCTs?", "answer": "Ceftazidime-avibactam was compared with meropenem in 106 patients with 3GCephRE."},
    {"question": "What is the suggested treatment for patients with severe infections due to CRE, if the bacteria are resistant to all other antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam?", "answer": "Cefiderocol is conditionally recommended for treatment, with low certainty of evidence."},
    {"question": "What is the probability of a better outcome with ceftazidime-avibactam compared to colistin for the treatment of CRE infections?", "answer": "The overall probability for a better outcome with ceftazidime-avibactam is 64% (95% CI 57%-71%) compared to colistin for the treatment of CRE infections."},
    {"question": "What are the mechanisms of resistance to ceftazidime-avibactam in bla KPC-2 and bla KPC-3 isolates?", "answer": "The mechanisms of resistance include increased hydrolysis of ceftazidime and amino acid insertion, substitution or deletion in the U loop of the KPC protein, disrupting the ability of ceftazidime-avibactam to bind at the active site."},
    {"question": "What is the level of evidence for the advantage of ceftazidime-avibactam over polymyxins for CRE susceptible to ceftazidime-avibactam?", "answer": "The level of evidence is low-certainty, based on observational study designs, focusing on K. pneumoniae and combination treatments used."},
    {"question": "What types of beta-lactamases does vaborbactam inhibit to restore meropenem activity?", "answer": "Vaborbactam inhibits class A and C beta-lactamases, but it is inactive against MBL and OXA-48 producers."},
    {"question": "What types of carbapenem-resistant Enterobacteriaceae (CRE) are susceptible to imipenem-relebactam synergy?", "answer": "Imipenem-relebactam synergy is effective against CRE producing KPC or combining AmpC or ESBL with reduced permeability, but it is poorly active against OXA-48 producers."},
    {"question": "What is the comparative efficacy of cefiderocol versus carbapenems for certain infections caused by carbapenem-susceptible Gram-negative bacteria (GNB)?", "answer": "Cefiderocol is non-inferior to carbapenems for urinary tract infections (UTI) and hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) caused by carbapenem-susceptible GNB."},
    {"question": "What is the unique characteristic of aztreonam in terms of its activity against carbapenem-resistant Enterobacteriaceae (CRE) infections?", "answer": "Aztreonam is uniquely active against MBL-producing CRE, although there is no clinical experience evaluating its use as monotherapy in the treatment of CRE infections."},
    {"question": "What was the observed outcome in a small retrospective study comparing colistin with ceftazidime-avibactam for the treatment of CRE infections?", "answer": "Higher mortality was observed among patients with CRE infections treated with colistin compared with ceftazidime-avibactam in a small retrospective study using inverse probability of treatment weighting adjustment."},
    {"question": "What is the suggestion from the CRaCKle cohort studies regarding the use of aminoglycoside-containing regimens versus tigecycline-containing regimens for CRE infections?", "answer": "The studies suggest better clinical outcomes with aminoglycoside-containing regimens compared with tigecycline-containing regimens."},
    {"question": "What is the comparative efficacy of tigecycline versus aminoglycosides for complicated urinary tract infections (cUTI) caused by carbapenem-resistant Enterobacteriaceae (CRE)?", "answer": "Tigecycline is inferior to aminoglycosides for cUTI caused by CRE, with moderate certainty of the evidence."},
    {"question": "What is the current state of evidence for the use of intravenous fosfomycin in treating CRE?", "answer": "The potential efficacy of intravenous fosfomycin for CRE has been described in in vitro studies and small case series, but the clinical response has been variable."},
    {"question": "What was the outcome of using trimethoprim-sulfamethoxazole-based schemes in patients with trimethoprim-sulfamethoxazole-susceptible CRE infections in the CRaCKle prospective cohort?", "answer": "The mortality rates were comparable to other treatments, but subsequent isolates were found to be resistant to trimethoprim-sulfamethoxazole in three out of four available follow-up cultures."},
    {"question": "What is the difference in in vitro activity between eravacycline and tigecycline against Gram-negative bacteria?", "answer": "Eravacycline has a two-fold higher in vitro activity compared with tigecycline against Gram-negative bacteria."},
    {"question": "What were the all-cause mortality rates at 28 days in the CARE-RCT study comparing plazomicin combination therapy with colistin combination therapy for the treatment of CRE infections?", "answer": "The all-cause mortality rates at 28 days were 8/20 (6/15 with bloodstream infections (BSI)) with colistin combination therapy and 2/17 (1/14 with BSI) with plazomicin combination therapy."},
    {"question": "What is the recommendation for patients with CRE infections susceptible to and treated with ceftazidime-avibactam, meropenem-vaborbactam, or cefiderocol?", "answer": "It is strongly recommended against using combination therapy in these patients, with low certainty of evidence."},
    {"question": "What is the suggestion for clinicians regarding carbapenem-based combination therapy for CRE infections?", "answer": "Clinicians should avoid carbapenem-based combination therapy for CRE infections, unless the meropenem MIC is 8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination therapy."},
    {"question": "What is the outcome of studies assessing mortality in patients with CRE infections receiving antibiotic combination versus monotherapy?", "answer": "The results of 35 studies are conflicting."},
    {"question": "What is the evidence suggesting in terms of clinical outcomes when comparing single versus multiple-covering therapy for CRE infections?", "answer": "The evidence favours combination therapy over monotherapy, with better clinical outcomes."},
    {"question": "What types of infections were evaluated in the AIDA and OVERCOME trials for the efficacy of colistin monotherapy versus colistin-meropenem combination therapy?", "answer": "The trials evaluated severe infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB), mainly hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) and bloodstream infections (BSI)."},
    {"question": "In patients with bloodstream infections (BSI) and non-bacteraemic infections due to KPC-producing K. pneumoniae, what was the association between combination therapy including a carbapenem and 14-day mortality?", "answer": "Combination therapy including a carbapenem was associated with lower 14-day mortality when the meropenem MIC were 8 mg/L."},
    {"question": "What is the evidence for the advantage of high-dose extended-infusion meropenem-polymyxin combination therapy over polymyxin monotherapy in treating severe CRE infections?", "answer": "There is low-certainty evidence for an advantage of high-dose extended-infusion meropenem-polymyxin combination therapy over polymyxin monotherapy in treating severe infections caused by CRE, mainly KPC-producing K. pneumoniae."},
    {"question": "What was the outcome of comparing ceftazidime-avibactam in combination with other antibiotics versus ceftazidime-avibactam monotherapy in patients with mixed infections caused by KPC and OXA-48 producers?", "answer": "There was no difference in mortality and clinical failure between the two treatment approaches."},
    {"question": "What is the effect of combining ceftazidime-avibactam with aztreonam on MBL producers?", "answer": "The combination is active in vitro against a substantial proportion of MBL producers, providing a potential treatment option where few others exist."},
    {"question": "What is the name of the Randomized Controlled Trial (RCT) mentioned in the context?","answer": "The name of the RCT is CREDIBLE."},
    {"question": "What effect do in vitro studies show when polymyxin is used?","answer": "In vitro studies show a reduction in resistance development when polymyxin is used."},
    {"question": "What is the suggested therapy for patients with severe infections due to DTR-CRPA, if active in vitro?","answer": "The suggested therapy is ceftolozane-tazobactam, with a conditional recommendation for use and very low certainty of evidence."},
    {"question": "What is the current state of clinical evidence on the management of DTR-CRPA?", "answer": "The clinical evidence on management of DTR-CRPA is highly limited, with no high-certainty evidence pointing to a preferred antibiotic treatment for CRPA."},
    {"question": "What was the outcome of the RESTORE-IMI 1 trial in terms of overall response to treatment at 28 days for patients with CR-GNB infections, particularly CRPA?", "answer": "The trial showed a favourable overall response to treatment at 28 days in 13/16 patients allocated to imipenem-relebactam compared to 5/8 patients allocated to colistin with imipenem, with an adjusted difference of 3.1 (95% CI -19.8 to 38.2)."},
    {"question": "What was the clinical cure rate of ceftolozane-tazobactam versus meropenem in patients with XDR-PA treated for nosocomial pneumonia in the ASPECT-NP trial?", "answer": "The clinical cure rate was 4/10 with ceftolozane-tazobactam versus 2/5 with meropenem."},
    {"question": "What is the conclusion regarding the evidence for non-inferiority of imipenem-relebactam compared with colistin-meropenem combination therapy for CRPA infections?", "answer": "The evidence is of very-low-certainty for non-inferiority of imipenem-relebactam compared with colistin-meropenem combination therapy for CRPA infections."},
    {"question": "What was the outcome of the CREDIBLE RCT in terms of mortality, clinical cure, and microbiological persistence for patients with baseline monomicrobial CRPA infections treated with cefiderocol versus BAT?","answer": "Mortality was similar, clinical cure and microbiological persistence were not different between the two groups, with very-low-certainty evidence for non-inferiority of cefiderocol compared with BAT."},
    {"question": "What was the outcome of the retrospective cohort study comparing high-dose doripenem infusion with colistin, both combined with fosfomycin, in patients with nosocomial pneumonia caused by CRPA?","answer": "Unadjusted all-cause 30-day mortality, clinical cure rates, and microbiological cure rates were not different between the two groups."},
    {"question": "What was the finding of the before-after retrospective study comparing the nephrotoxicity of colistin and polymyxin B among critically ill patients with severe infections caused by MDR P. aeruginosa and A. baumannii?","answer": "The study found that colistin was associated with higher RIFLE-defined nephrotoxicity compared to polymyxin B, with an adjusted hazard ratio of 2.27 (95% CI 1.35-3.82)."},
    {"question": "What is the recommendation for the use of combination therapy with new BLBLI or cefiderocol for CRPA infections?","answer": "There is no recommendation for or against the use of combination therapy with new BLBLI or cefiderocol for CRPA infections due to lack of evidence."},
    {"question": "What is the availability of data on combination therapy for DTR-CRPA?","answer": "There is a paucity of data on combination therapy for DTR-CRPA."},
    {"question": "What was the outcome of the AIDA and OVERCOME RCTs comparing colistin with colistin-carbapenem therapy for severe P. aeruginosa infections?","answer": "There were no significant differences in 28-day mortality between the two treatment groups in both RCTs."},
    {"question": "What is the evidence for the advantage of polymyxin combination therapy over polymyxin alone or combined with inactive antibiotics for CRPA?","answer": "There is very low-certainty evidence for an advantage of polymyxin combined with another active antibiotic over polymyxin alone or combined with inactive antibiotics."},
    {"question": "What was the outcome of the cohort study comparing ceftolozane-tazobactam monotherapy with combination therapy for MDR-or XDR-P. aeruginosa infections?","answer": "There was no difference in cure rates between patients treated with ceftolozane-tazobactam monotherapy (66.7%) and those treated with ceftolozane-tazobactam in combination with colistin or an aminoglycoside (60%)."},
    {"question": "What antibiotic is suggested for patients with CRAB susceptible to sulbactam and HAP/VAP?","answer": "Ampicillin-sulbactam is suggested for patients with CRAB susceptible to sulbactam and HAP/VAP, although this is a conditional recommendation based on low certainty of evidence."},
    {"question": "What antibiotics can be used for patients with CRAB resistant to sulbactam?","answer": "For patients with CRAB resistant to sulbactam, a polymyxin or high-dose tigecycline can be used if active in vitro, although there is no preferred antibiotic recommended due to lack of evidence. Additionally, cefiderocol is conditionally not recommended for the treatment of CRAB infections due to low certainty of evidence."},
    {"question": "What is the most common infection associated with CRAB, and what is a limitation of colistin's use in this context?","answer": "The most common infection associated with CRAB is pneumonia, frequently ventilator-associated pneumonia (VAP). A limitation of colistin's use in this context is that its concentrations in epithelial lining fluid after intravenous administration are negligible."},
    {"question": "What was the outcome of a small RCT comparing polymyxins (mostly colistin) with ampicillin-sulbactam in patients with VAP caused by CRAB?","answer": "The small RCT found no difference between ampicillin-sulbactam and colistin in terms of mortality, clinical failure, or microbiological failure in ICU patients with VAP caused by CRAB susceptible to ampicillin-sulbactam."},
    {"question": "What type of studies compared colistin with tigecycline, and what was the typical patient population and treatment approach in these studies?","answer": "Four retrospective observational studies compared colistin with tigecycline, primarily in ICU patients with pneumonia, and often in combination with other antibiotics."},
    {"question": "What is cefiderocol and how was it evaluated for CR-GNB infections?","answer": "Cefiderocol is a novel siderophore cephalosporin with an MIC 90 for A. baumannii in the range of 1-8 mg, and it was compared with best available therapy (BAT) for CR-GNB infections in the CREDIBLE RCT."},
    {"question": "What is eravacycline and how does its activity against CRAB compare to tigecycline, and what type of infections was it evaluated for in RCTs?","answer": "Eravacycline is a novel synthetic fluorocycline that has two-to eight-fold lower MICs than tigecycline against CRAB, and it was evaluated in two RCTs for the treatment of complicated intra-abdominal infections (cIAI) compared with ertapenem and meropenem."},
    {"question": "What type of studies evaluated the use of aminoglycosides for the treatment of CRAB infections?","answer": "Small retrospective studies evaluated the treatment with aminoglycosides for CRAB infections."},
    {"question": "What is the basis for suggesting combination therapy for CRAB, and which antibiotics have been identified as potential combination partners?","answer": "Combination therapy for CRAB has been suggested based on in vitro studies showing synergistic interactions between polymyxins and certain carbapenems, specifically meropenem, imipenem, and doripenem."},
    {"question": "What was the focus of the AIDA RCT, and how many patients with CRAB infections were included in the study?","answer": "The AIDA RCT assessed the combination of colistin with meropenem and included 406 patients with CR-GNB overall, with 312 of those patients having CRAB bacteraemia, ventilator-associated pneumonia (VAP), or hospital-acquired pneumonia."},
    {"question": "What is the association between the use of polymyxins and carbapenems combination and patient outcomes in observational studies?","answer": "The combination of polymyxins and carbapenems is significantly associated with survival or clinical cure in observational studies."},
    {"question": "What is the evidence level for carbapenem-polymyxin combination therapies in treating CRAB infections based on a randomized controlled trial (RCT)?","answer": "The evidence level is high-certainty evidence against the use of carbapenem-polymyxin combination therapies for CRAB infections, as shown in a randomized controlled trial (RCT) with a considerable sample of patients with severe, high-risk infections."},
    {"question": "How many randomized controlled trials (RCTs) have assessed the combination of colistin with rifampin as a therapy?","answer": "Three randomized controlled trials (RCTs) have assessed the combination of colistin with rifampin as a therapy."},
    {"question": "What is the study design and patient population of the study that assessed the combination of colistin-vancomycin compared to colistin monotherapy?","answer": "The study that assessed the combination of colistin-vancomycin compared to colistin monotherapy was a retrospective observational study conducted among 57 patients in the Intensive Care Unit (ICU) with mostly CRAB pneumonia."},
    {"question": "What is the condition under which double covering therapy might be considered for CRAB infections, and what is an example of a studied combination therapy?","answer": "Double covering therapy might be considered if the CRAB is susceptible to more than one antibiotic. An example of a studied combination therapy is the combination of colistin and ampicillin-sulbactam, which was assessed in a small RCT including 49 patients in ICU with ventilator-associated pneumonia (VAP) caused by CRAB susceptible to ampicillin-sulbactam."},
    {"question": "What is recommended for optimal antibiotic dosing schemes, and where can healthcare professionals find guidance on recommended dosing?","answer": "Optimal antibiotic dosing schemes should be used, with attention to adverse effects, and dosing and mode of administration should be optimized by pathogen and indication, with use of therapeutic drug monitoring whenever available. Healthcare professionals can refer to EUCAST's recommended dosing for guidance (https://www.eucast.org/clinical_breakpoints/)."},
    {"question": "What is the primary concern related to antibiotic stewardship in the current guideline, and how are the recommendations tailored to address this concern?","answer": "The primary concern is the use of carbapenems for infections caused by 3GcephRE, and the recommendations are tailored to address this by considering sepsis severity and source of infection, allowing for carbapenem-sparing therapy for non-severe infections and low-risk sources of infection, and addressing stepdown therapy."},
    {"question": "What is the challenge in antibiotic stewardship during the empirical treatment phase for patients at high risk of CR-GNB infections, and how should local guidelines address this?","answer": "The challenge is balancing the need to achieve appropriate empirical antibiotic therapy for patients with CR-GNB infections and conserving last resort therapies for these bacteria. Local guidelines should address the empirical treatment phase, guided by local epidemiology, to strike this balance."},
    {"question": "What type of guidance documents did the Infectious Diseases Society of America recently publish, and what organisms do they address?", "answer": "The Infectious Diseases Society of America recently published guidance documents on the treatment of 3GcephRE, CRE, DTR P. aeruginosa, and CRAB."},
    {"question": "What is a significant challenge to the use of new antibiotics in low-resource settings, and what is proposed to address this issue?", "answer": "The significant challenge is the high cost of new antibiotics, which may prohibit their use in low-resource settings. To address this, it is proposed that antibiotics critical to managing priority pathogens should be defined, and efforts should be made to ensure their universal availability, with differential costs considered for different socio-economic settings to promote better equity in patient management."}
]